Genmab A/S (GMAB): Price and Financial Metrics


Genmab A/S (GMAB)

Today's Latest Price: $28.97 USD

0.71 (-2.39%)

Updated Jun 4 6:55pm

Add GMAB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

GMAB Daily Price Range
GMAB 52-Week Price Range

GMAB Stock Price Chart More Charts


GMAB Price/Volume Stats

Current price $28.97 52-week high $31.30
Prev. close $29.68 52-week low $16.24
Day low $28.69 Volume 1,902,800
Day high $29.36 Avg. volume 645,748
50-day MA $25.12 Dividend yield N/A
200-day MA $22.62 Market Cap 18.91B

Genmab A/S (GMAB) Company Bio


Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.


GMAB Latest News Stream


Event/TimeNews Detail
Loading, please wait...

GMAB Latest Social Stream


Loading social stream, please wait...

View Full GMAB Social Stream

Latest GMAB News From Around the Web

Below are the latest news stories about Genmab A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Biotech ETFs Are Soaring. These Four Are Still Worth Considering.

Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even though these ETFs have risen, they could have farther to go.

Yahoo | June 1, 2020

Genmab's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Genmab.

Yahoo | May 20, 2020

How Does Genmab's (CPH:GMAB) P/E Compare To Its Industry, After Its Big Share Price Gain?

Genmab (CPH:GMAB) shareholders are no doubt pleased to see that the share price has had a great month, posting a 34...

Yahoo | May 13, 2020

Genmab A/S (GMAB) Q1 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to Genmab's First Quarter Report 2020 Conference Call. Genmab is not under an obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward.

Yahoo | May 7, 2020

Genmab A/S to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Genmab A/S (NASDAQ:GMAB) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 6, 2020 at 6:00 PM Eastern Time. ...

Yahoo | May 6, 2020

Read More 'GMAB' Stories Here

GMAB Price Returns

1-mo 13.47%
3-mo 23.22%
6-mo 21.72%
1-year 66.59%
3-year 31.66%
5-year 234.37%
YTD 29.74%
2019 35.54%
2018 -0.61%
2017 -0.04%
2016 23.73%
2015 128.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8899 seconds.